Please assess the completion status of the following clinical trial:

Trial Title: IPT and Efficacy of Sulphadoxine/Pyrimethamine and Chlorproguanil/Dapsone in 6-59 Month Old Children With Malaria.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
For 6-59 month study~Inclusion Criteria:~* Aged 6-59 months~* Weight of 4.5 Kgs or greater.~* Not enrolled in IPTi trial~* Absence of severe malnutrition (defined as a child whose weight-for-height is below 3 standard deviations of less than 70% of the median of WHO reference values, or who has symmetrical edema involving at least the feet)~* A slide-confirmed infection with P. falciparum only~* Initial parasite density between 2,000 and 200,000 asexual parasites per microliter.~* Absence of general danger signs among children \< 5 years (see below) Measured axillary temperature ³37.5 °C~* Ability to attend stipulated follow-up visits~* Informed consent provided by parent/guardian~* Absence of history of hypersensitivity reactions to any of the drugs being evaluated~Exclusion Criteria:~* Enrolled in IPTi trial~* Severe malnutrition (defined as above)~* No slide confirmed infection with P. falciparum~* Initial parasite density \< 2,000 or \> 200,000 asexual parasites per microliter.~* Presence of general danger signs among children \< 5 years (inability to drink or breastfeed; vomiting everything; recent history of convulsions; lethargy or unconsciousness; inability to sit or stand up) or other signs of severe and complicated falciparum malaria according to WHO definitions~* Measured axillary temperature \<37.5 °C~* Inability to attend stipulated follow-up visits~* Informed consent not provided by parent/guardian~* History of hypersensitivity reactions to any of the drugs being evaluated~For 2-10 month study~Inclusion criteria.~* Aged 2-10 months~* Weight of 4.5 Kgs or greater.~* Not enrolled in IPTi trial~* Absence of severe malnutrition~* A slide-confirmed infection with P. falciparum only~* Any parasite density assessed by research microscopists.~* Absence of general danger signs among children \< 5 years (inability to drink or breastfeed; vomiting everything; recent history of convulsions; lethargy or unconsciousness; inability to sit or stand up) or other signs of severe and complicated falciparum malaria according to WHO definitions~* Measured axillary temperature \< 37.5 °C~* Ability to attend stipulated follow-up visits~* Informed consent provided by parent/guardian~* Absence of history of hypersensitivity reactions to SP.~Exclusion criteria are not listed separately in the WHO protocol, as they are the opposite of the inclusion criteria.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): SP in symptomatic children aged 6-59 months
- B (Type: EXPERIMENTAL): SP to asymptomatic infected children aged 2-10 months
- C (Type: EXPERIMENTAL): Chlorproguanil/dapsone in symptomatic 6-59 month old children

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy